Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;10(1):456-462.
doi: 10.1080/21623945.2021.1980258.

Adipocytokines in Graves' orbitopathy and the effect of high-dose corticosteroids

Jan Schovanek  1 , Michal Krupka  2 , Lubica Cibickova  1 , Marta Karhanova  3 , Sunaina Reddy  1 , Veronika Kucerova  4 , Zdenek Frysak  1 , David Karasek  1
Affiliations

Adipocytokines in Graves' orbitopathy and the effect of high-dose corticosteroids

Jan Schovanek et al. Adipocyte. 2021 Dec.

Abstract

Graves' orbitopathy (GO) is a serious, progressive eye condition seen in patients with autoimmune thyroid disease. GO is characterized by inflammation and swelling of soft orbital tissues. Adipose tissue produces cytokine mediators called adipokines. The present study focuses on the relationship between serum levels of selected adipokines in patients with GO, comparing them with the control group, and uniquely describes the effect of high-dose systemic corticosteroids (HDSC) on their levels. For the purposes of this study, we collected blood samples before and after the treatment with HDSC from 60 GO patients and 34 control subjects and measured serum levels of adiponectin, AIF-1, A-FABP and FGF-21. Levels of adiponectin significantly differed among the three study groups (ANOVA p = 0.03). AIF-1 levels were also significantly different among the study groups (ANOVA p < 0.0001). AIF-1 was significantly associated with the presence of GO after adjusting for clinical factors (age, sex, smoking and BMI) and level of TSH (odds ratio 1.003, p < 0.01). This finding could enforce targeting macrophages in treatment strategies for GO since AIF-1 is considered as a marker of their activation.

Keywords: Graves’ orbitopathy; adipokines; methylprednisolone.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Levels of studied adipokines in controls, patients before HDSC and after HDSC. Panel A: adiponectin (μg/ml); Panel B: AIF-1 (pg/ml); Panel C: A-FABP (ng/ml); Panel D: FGF-21 (pg/ml). Y axis concentrations are in log 10. *p < 0.05 and †p < 0.001 in patients before treatment vs. control group, @p < 0.001 in patients after treatment vs. control group
See this image and copyright information in PMC

References

    1. Rotondo Dottore G, Bucci I, Lanzolla G, et al. Genetic profiling of orbital fibroblasts from patients with graves’ orbitopathy. J Clin Endocrinol Metab. 2021;106(5):e2176–e90. - PubMed
    1. Lacheta D, Miskiewicz P, Gluszko A, et al. Immunological aspects of graves’ ophthalmopathy. Biomed Res Int. 2019;2019:7453260. - PMC - PubMed
    1. Rotondo Dottore G, Torregrossa L, Caturegli P, et al. Association of T and B cells infiltrating orbital tissues with clinical features of graves orbitopathy. JAMA Ophthalmol. 2018;136(6):613–619. - PMC - PubMed
    1. Dik WA, Virakul S, van Steensel L.. Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves’ ophthalmopathy. Exp Eye Res. 2016;142:83–91. - PubMed
    1. Li H, Fitchett C, Kozdon K, et al. Independent adipogenic and contractile properties of fibroblasts in graves’ orbitopathy: an in vitro model for the evaluation of treatments. PLoS One. 2014;9:4. - PMC - PubMed

Publication types